Latest reports
The ESG Performance Report includes our performance across our six environmental, social and governance (ESG) priority areas, and includes ESG data for current and previous years. Within the Responsible Business section of our Annual Report, we provide a summary and highlights of our progress in 2023.
Our position on
Learn more about our views and our practices across a range of access, R&D, intellectual property, health security and environment issues here.
ESG reports archive
Search our archive of responsible business reports and resources dating back to 2002.
ESG ratings performance
Detailed below is how we perform in key ESG ratings.
| External benchmarking | Current rating |
Previous rating |
Comments |
|---|---|---|---|
| S&P Global's Corporate Sustainability Assessment | 84 | 86 | 1st in the pharmaceutical industry group; Assessment conducted annually, current score updated Nov 2023 |
| Access to Medicines Index | 4.06 | 4.23 | Led the bi-annual index since its inception in 2008; Updated bi-annually, current results from Nov 2022 |
| Antimicrobial Resistance Benchmark | 84% | 86% | Led the bi-annual benchmark since its inception in 2018; Current ranking updated Nov 2021 |
| CDP Climate change | A- | A- | Updated annually, current score updated Feb 2024 |
| CDP Water security | A- | B | Updated annually, current score updated Feb 2024 |
| CDP Forests (palm oil) | B | A- | Updated annually, current score updated Feb 2024 |
| CDP Forests (timber) | B | B | Updated annually, current score updated Feb 2024 |
| CDP Supplier engagement rating | Leader | Leader | Updated annually, current score updated March 2023 |
| Sustainalytics | 16.7 | 18.6 | 1st percentile in pharma subindustry group; Lower score represents lower risk. Current ranking updated September 2023 |
| MSCI | AA | AA | Last rating action date: September 2023 |
| Moody's ESG solutions | 62 | 61 | 2nd in the pharmaceutical sector; Current score updated August 2023 |
| ISS Corporate Rating | B+ | B+ | Current score updated June 2023 |
| FTSE4Good | Member | Member | Member since 2004, latest review in June 2023 |
| ShareAction’s Workforce Disclosure Initiative | 79% | 77% | Current score updated Jan 2024 |
Updated February 2024
Disclosure
We publish our charitable giving data in our Annual Report and ESG performance summary each year. We are further increasing transparency by publishing details of our individual charitable grants over £10,000 ($15,000). Details of the grants are available in the Charitable Grants report 2023 (PDF 467KB).
In addition to the grants of £10,000 or more declared here, GSK discloses grants to US-based non-profit organisations that foster increased understanding of scientific, clinical, and healthcare issues and contribute to improving patient care.
GSK is a member of many trade and industry associations that primarily represent pharmaceutical, consumer products and vaccine businesses at the national, regional and international levels.
Trade Association Membership 2023 (PDF - 121.4KB)
Global
Global Allergy and Asthma Patient Platform (GAAPP) (PDF-195KB)
International Alliance of Patient Organisations (IAPO) (PDF-456KB)
International Gynecologic Cancer Society (IGCS) (PDF-258KB)
Meningitis Research Foundation (MRF) (PDF-203KB)
World Hepatitis Alliance (WHA) (PDF-392KB)
World Ovarian Cancer Coalition (WOOC) (PDF-219KB)
UK
Kidney Wales Foundation (PDF-43KB)
National Kidney Federation (PDF-44KB)
Ovarian Cancer Action (PDF-43KB)
Patient Association (PDF-43KB)
Shine Cancer Support (PDF-24KB)
Target Ovarian Cancer (PDF-24KB)
The Polycystic Kidney Disease Charity (PDF-24KB)
PAG disclosure 2021 (PDF-196KB)
PAG disclosure 2020 (PDF-627KB)
GSK also provides funding to support UK community healthcare charities through the GSK IMPACT Awards, in partnership with The King’s Fund. This annual programme recognises and promotes excellence in community healthcare, providing funding and training to help strengthen the award winners’ current management plans and support their future aspirations.
BHA for Equality in Health Social Care (PDF-23KB)
Mancroft Advice Project (PDF-23KB)
The Brigstowe Project (PDF-23KB)
Americas
Asia Pacific
Europe
European Cancer Patient Coalition (ECPC) (PDF-206KB)
European Federation of Allergy and Airways Disease Patients Association (PDF-197KB)
European Network of Gynaecological Cancer Advocacy Groups (ENGAGe) (PDF-206KB)
European Patients' Forum (PDF-272)
Myeloma Patients Europe (PDF-246KB)
Sarcoma Patients EuroNet (SPAEN) (PDF-343KB)
We are committed to disclosing the payments we make, as we work together with healthcare professionals. Find our disclosure reports at Engaging with healthcare professionals.
